首页 > 市场调查报告书 > 製药

非专利药

市场调查报告书

商品编码

1793487

学名药的全球市场:适应症 (中枢神经系统·循环系统·泌尿系统·肿瘤·呼吸系统·其他)·给药途径·流通管道·各地区 (～2035年)

Global Generic Drugs Market Research Report by Indication (Central Nervous System, Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration, by Distribution Channel, and by Region Forecast till 2035

出版日期: 2025年07月08日 | 出版商:

Market Research Future | 英文 143 Pages | 订单完成后即时交付

价格

简介目录图表

预计到 2035 年，全球仿製药市场规模将成长两倍，年均成长率稳定在 9.36%，达到 11,485.5 亿美元。

慢性病的增多是全球仿製药市场成长的主要推动因素。癌症、心臟病、癫痫和关节炎等疾病的快速增长催生了对平价治疗的需求。仿製药能够以更低的价格提供与品牌药相同的治疗效果，有时是精打细算的患者和医疗保健系统的唯一选择。市场参与者正在透过推出新产品、扩大现有设施以及拓展新的治疗领域来加强其供应。

另一方面，由于品质和安全问题而导致的产品自愿召回仍然是仿製药产品供应和信任度下降的主要障碍。此外，医护人员对品牌药的忠诚度也限制了仿製药的采用，导致许多人继续开立熟悉的品牌药。

同时，研发投入促进了高品质仿製药的生产，从而带来了尖端技术的引进和市场扩张。全球老化也是一个关键因素，老年人占了相当大的市场占有率，支撑着对慢性病治疗的需求。预计到2050年，亚太地区老年人口将翻一番，提供价格实惠的药品将成为当务之急。这些趋势，加上政府的支持性政策，很可能将确保仿製药在全球医疗保健服务中继续占领先地位。

区域分析

在北美，抑制医疗成本上涨的需求支撑了仿製药市场。美国凭藉其广泛的製造网络和清晰的法律框架（允许专利到期和仿製药替代）成为区域领导者。患者对仿製药的接受度正在不断提高，这支撑了强劲的销售业绩，尤其是在心臟病学、肿瘤学和抗生素领域。加拿大强调成本效益的医疗政策也稳步支持仿製药的广泛采用。

欧洲市场受益于清晰的监管环境和公共医疗体系对低价的重视。德国、西班牙和英国是主要的消费国，各国的医疗保健服务都鼓励仿製药的处方。东欧国家药品可及性的提高和中产阶级人口的成长正在推动仿製药的需求。具有竞争力的价格和支援性的法律框架正在推动区域成长。

亚太地区是成长最快的地区，这在很大程度上得益于印度和中国的製造能力。印度在以最合理的价格供应高品质仿製药方面处于全球领先地位，而中国也受益于重大的医疗改革。人口结构变化和慢性病发病率上升推动了对平价药品的需求。包括韩国和泰国在内的越来越多的国家正在积极使用仿製药来降低医疗成本。本报告探讨了全球仿製药市场，并提供了市场定义和概述、影响市场成长的各种因素分析、市场规模趋势和预测、按细分市场、地区和主要国家/地区进行的细分、竞争格局以及主要公司的概况。

Global Generic Drugs Market Research Report by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and by Region (North America, Europe, Aia-Pacific, Rest of the World) Forecast till 2035

Industry Overview

The global generic drugs market is expected to nearly triple to USD 1,148.55 billion by 2035, driven by steady annual growth of 9.36%. A generic drug is a pharmaceutical product equivalent in dosage, strength, safety, and intended use to a branded medicine but sold under its chemical name. These drugs are typically marketed after patent protection ends, making them a cost-effective option for patients and healthcare systems.

The prevalence of chronic illnesses has been identified as a significant factor contributing to the growth of the global generic medication market. Cancer, heart disease, and other conditions like these have increased dramatically, and this is the case with the rise of epilepsy and arthritis, resulting in the need for low-cost treatment. Generic medicines deliver therapeutic benefits similar to those of branded drugs but at a much lower price; therefore, they become the only option for patients and healthcare systems that face difficult situations with their budgets. The players of the market are intensifying their supply by launching new products, extending their existing facilities, and entering into new therapeutic areas.

Nevertheless, voluntary product recalls caused by quality or safety issues remain a major obstacle to the availability of products and confidence in generics. Brand loyalty of healthcare professionals is one of the factors that limits wider adoption. Those who have not changed their minds still continue prescribing the branded medicines that they are familiar with to the patients.

At the same time, the act of allocating money to R&D allows the production of high-quality generics, which includes the implementation of advanced technology and the expansion of the market reach. The increasing age of the world population is one of the key factors that pushes up senior consumers, who make up a large portion of the market for chronic disease medication. By 2050, the old people in the Asia-Pacific is expected to be twice as many as they are now; therefore, affordable medicines will be the topmost issue. If these trends, combined with favorable government policies, continue to prevail, generic drugs will remain at the forefront of providing global healthcare.

Industry Segmentations

In terms of indication, the global drugs market is segmented into central nervous system (CNS), cardiovascular, urology, oncology, respiratory, and others.

The global market is classified based on the route of administration, comprising oral, topical, parenteral, and others.

Depending on the distribution channel, the global generic drug market is divided into hospital, retail, and online pharmacy.

Regional Analysis

In North America, the generic drugs market is bolstered by the need to control rising healthcare costs. The US is the leader in the region with a vast network of manufacturers and a legal framework that is clearly defined and enables patent expiry and generic substitution. Patient acceptance of generics, which is growing, has made it possible to keep a strong sales record, especially in cardiovascular, oncology, and antibiotic segments. Canadian healthcare policies that promote cost efficiency are hence one of the factors that allow generics to be steadily taken up.

Europe's market is reaping the benefits from a regulatory environment that is clear and the presence of a strong public healthcare system that emphasizes affordability. Germany, Spain, and the UK are among the top consumers of this product, and their national health services are promoting generic prescriptions. The improvement in medicine accessibility, along with the increasing numbers of the middle-class population, are the main factors driving the catching up of Eastern European countries. Competitive pricing and supportive legislation are key growth factors in the region.

Asia-Pacific is the fastest-growing region, and most of the growth is coming from the manufacturing potential of Asia, particularly India and China. India is a global leader in supplying the highest quality generics at the most reasonable prices, and China's market is receiving the positive impact of healthcare reforms on a large scale. Due to demographic changes in the age structure of the population and rising prevalence of chronic diseases, the demand for cheap drugs has increased. Besides South Korea and Thailand, these countries are also among the most prolific users of generic medicine to reduce the cost of healthcare.

Latin America, the Middle East, and Africa are an increasing part of the generic medicines market on a global scale. With Brazil, there is a more aggressive push to increase local production, while Mexico benefits from cross-border trade with the US. Rising investment in pharmaceutical manufacturing in the Middle East is contributing to the region's effort to become more self-sufficient. African countries are setting the availability of drugs and the strengthening of distribution channels for generics as their top priorities.

Key Players

Major players in the global generic drugs market are Teva Pharmaceuticals Industries Ltd., Novartis AG, Viatris, Inc., Sun Pharmaceuticals Industries, Fresenius Kabi, Lupin Pharmaceuticals, Inc., Endo International plc, Aurobindo Pharma, Aspen Holdings, Cipla Ltd., and Fresenius SE & Co. KGaA.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
- 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
- 4.2.3 RISING DEMAND FOR AFFORDABLE MEDICATIONS
4.3 RESTRAINTS
- 4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
- 4.3.2 BRAND LOYALTY AND DOCTOR PREFERENCES
4.4 OPPORTUNITY
- 4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE
- 4.4.2 RISING AGING POPULATION

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET

6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

6.1 OVERVIEW
6.2 CENTRAL NERVOUS SYSTEM (CNS)
6.3 CARDIOVASCULAR
6.4 UROLOGY
6.5 ONCOLOGY
6.6 RESPIRATORY
6.7 OTHERS

7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

7.1 OVERVIEW
7.2 ORAL
7.3 TOPICAL
7.4 PARENTERAL
7.5 OTHERS

8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

8.1 OVERVIEW
8.2 HOSPITAL PHARMACY
8.3 RETAIL PHARMACY
8.4 ONLINE PHARMACY

9 GLOBAL GENERIC DRUGS MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 INDIA
- 9.4.3 JAPAN
- 9.4.4 SOUTH KOREA
- 9.4.5 AUSTRALIA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2024
10.3 COMPETITOR DASHBOARD
10.4 PUBLIC PLAYERS STOCK SUMMARY
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH
- 10.6.2 PRODUCT LAUNCH / PRODUCT APPROVAL
- 10.6.3 EXPANSION

11 COMPANY PROFILES

11.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 LUPIN PHARMACEUTICALS, INC.
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 ENDO INTERNATIONAL PLC
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 AUROBINDO PHARMA
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 ASPEN HOLDINGS
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 CIPLA LTD
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 NOVARTIS AG
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 FRESENIUS SE & CO. KGAA
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 VIATRIS INC.
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 DATA CITATIONS

简介目录图表

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 3 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019-2035 (USD BILLION)
TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019-2035 (USD BILLION)
TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019-2035 (USD BILLION)
TABLE 6 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019-2035 (USD BILLION)
TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019-2035 (USD BILLION)
TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019-2035 (USD BILLION)
TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019-2035 (USD BILLION)
TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019-2035 (USD BILLION)
TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019-2035 (USD BILLION)
TABLE 14 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019-2035 (USD BILLION)
TABLE 16 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019-2035 (USD BILLION)
TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019-2035 (USD BILLION)
TABLE 18 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019-2035 (USD BILLION)
TABLE 19 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 23 US GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 24 US GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 25 US GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 26 CANADA GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 27 CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 28 CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 29 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 30 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 31 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 32 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 33 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 34 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 35 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 36 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 37 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 38 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 39 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 40 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 41 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 42 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 43 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 44 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 45 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 46 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 47 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 48 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 49 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 50 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 51 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 52 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 53 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 54 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 55 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 56 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 57 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 58 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 59 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 60 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 61 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 62 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 63 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 64 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 65 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 66 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 67 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 68 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 69 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 70 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 71 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 72 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 73 REST OF THE WORLD: GENERIC DRUGS MARKET, BY COUNTRY, 2019-2035 (USD BILLION)
TABLE 74 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 75 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 76 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 77 MIDDLE EAST: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 78 MIDDLE EAST: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 79 MIDDLE EAST: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 80 AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 81 AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 82 AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 83 SOUTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019-2035 (USD BILLION)
TABLE 84 SOUTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD BILLION)
TABLE 85 SOUTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD BILLION)
TABLE 86 PUBLIC PLAYERS STOCK SUMMARY
TABLE 87 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 88 PRODUCT LAUNCH
TABLE 89 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 90 EXPANSION
TABLE 91 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED
TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
TABLE 93 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED
TABLE 94 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
TABLE 95 ENDO INTERNATIONAL PLC: PRODUCT OFFERED
TABLE 96 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS
TABLE 97 AUROBINDO PHARMA: PRODUCT OFFERED
TABLE 98 AUROBINDO PHARMA: KEY DEVELOPMENTS
TABLE 99 ASPEN HOLDINGS: PRODUCT OFFERED
TABLE 100 CIPLA LTD.: PRODUCTS OFFERED
TABLE 101 CIPLA LTD.: KEY DEVELOPMENTS
TABLE 102 NOVARTIS AG: PRODUCTS OFFERED
TABLE 103 NOVARTIS AG: KEY DEVELOPMENTS
TABLE 104 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED
TABLE 105 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 106 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED
TABLE 107 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS
TABLE 108 VIATRIS INC.: PRODUCT OFFERED
TABLE 109 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE
FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET
FIGURE 6 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2024 & 2035 (USD BILLION)
FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2024
FIGURE 9 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION)
FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024
FIGURE 12 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)
FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION)
FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024
FIGURE 15 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019 & 2035 (USD BILLION)
FIGURE 16 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2024
FIGURE 17 NORTH AMERICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2035 (USD BILLION)
FIGURE 18 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 19 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2024
FIGURE 20 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 21 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 22 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 23 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 24 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)
FIGURE 25 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)
FIGURE 26 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2024
FIGURE 27 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET
FIGURE 28 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS
FIGURE 32 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 CIPLA LTD.: FINANCIAL OVERVIEW
FIGURE 36 CIPLA LTD.: SWOT ANALYSIS
FIGURE 37 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 NOVARTIS AG: SWOT ANALYSIS
FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 41 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

02-2729-4219

+886-2-2729-4219

License/价格

学名药的全球市场:适应症 (中枢神经系统·循环系统·泌尿系统·肿瘤·呼吸系统·其他)·给药途径·流通管道·各地区 (～2035年)

Global Generic Drugs Market Research Report by Indication (Central Nervous System, Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration, by Distribution Channel, and by Region Forecast till 2035

区域分析

目录

第1章摘要整理

第2章市场概要

第3章调查手法

第4章市场动态

第5章市场要素分析

第6章全球学名药市场:各适应症

第7章全球学名药市场:各给药途径

第8章全球学名药市场:各流通管道

第9章全球学名药市场:各地区

第10章竞争情形

第11章企业简介

第12章资料的引用